New Protein PNA5 Offers Hope for Parkinson's Cognitive Symptoms

**Parkinson’s disease** is a degenerative neurological disorder primarily known for causing motor symptoms such as tremors, stiffness, and impaired balance. However, it also leads to cognitive decline, something existing treatments do not adequately address. Researchers at the University of Arizona Health Sciences have explored the potential of **PNA5**, a tiny protein, as a protective agent for brain cells. In their study, published in *Experimental Neurology*, PNA5 demonstrated protective effects in an animal model, focusing on cognitive symptoms of Parkinson’s disease. **Dr. Lalitha Madhavan** and her team, collaborating with Dr. Torsten Falk and Dr. Meredith Hay, found that PNA5 could mitigate the damaging effects of hyperactive microglia, a type of brain immune cell that can contribute to cognitive decline by promoting inflammation. Chronic inflammation, distinct from the temporary immune response to infection or injury, is thought to play a significant role in the progression of neurodegenerative diseases like Parkinson’s. The study suggests that PNA5 might reduce inflammation by dialing back the hyperactivity of microglia, allowing brain cells to maintain functionality. This could slow or prevent cognitive degradation. Dr. Hay and Dr. Robin Polt, working at the University of Arizona's BIO5 Institute, developed PNA5 by modifying a naturally occurring chemical to enhance its ability to penetrate and persist within the brain. The team is optimistic about PNA5's potential not only for Parkinson’s but also for other forms of dementia, including Alzheimer's. They aim to refine their research by identifying biomarkers, determining optimal dosages, and understanding sex differences in treatment impacts. This promising avenue could lead to new therapies for Parkinson's patients, providing hope for managing cognitive symptoms.